Literature DB >> 22071028

Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data.

Pongthorn Narongroeknawin1, Nivedita M Patkar, Bita Shakoory, Archana Jain, Jeffrey R Curtis, Elizabeth Delzell, Philip H Lander, Robert R Lopez-Ben, Michael J Pitt, Monika M Safford, David A Volgas, Kenneth G Saag.   

Abstract

Administrative claims databases have large samples and high generalizability. They have been used to evaluate associations of atypical femoral fractures with bisphosphonates. We developed and assessed accuracy of claims-based algorithms with hospital and physician diagnosis codes for these fractures. Medical records and radiology reports of all adults admitted at University of Alabama at Birmingham Health System from 2004 to 2008 with International Classification of Diseases, Ninth Revision hospital discharges and surgeons' fracture repair codes for subtrochanteric femoral fractures and random sample of other femoral fractures were reviewed. We identified 137 persons with suspected subtrochanteric femoral fractures and randomly selected 50 persons with either suspected diaphyseal femoral fractures or hip fractures other than subtrochanteric and diaphyseal femoral fractures (typical hip fractures). Eleven patients had radiographic features indicative of atypical femoral fractures. The positive predictive value (PPV) of claims-based algorithms varied with primary or secondary positions on discharge diagnoses and the sources of diagnosis codes. The PPV for fractures ranged 69-89% for subtrochanteric femoral, 89-98% for diaphyseal femoral, and 85-98% for typical hip fractures. The PPV of administrative codes for defining a femoral fracture as atypical was low and imprecise. Claims-based algorithms combining hospital discharges with surgeon's diagnosis codes had high PPV to identify the site of subtrochanteric or diaphyseal femoral fractures vs typical hip fractures. However, claims-based data were not accurate in identifying atypical femoral fractures. These claims algorithms will be useful in future population-based observational studies to evaluate associations between osteoporosis medications and subtrochanteric and diaphyseal femoral fractures. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22071028      PMCID: PMC4112756          DOI: 10.1016/j.jocd.2011.09.001

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  34 in total

1.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Authors:  D M Black; D E Thompson; D C Bauer; K Ensrud; T Musliner; M C Hochberg; M C Nevitt; S Suryawanshi; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

2.  Incidence and costs to Medicare of fractures among Medicare beneficiaries aged > or = 65 years--United States, July 1991-June 1992.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1996-10-18       Impact factor: 17.586

3.  Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.

Authors:  H A Pols; D Felsenberg; D A Hanley; J Stepán; M Muñoz-Torres; T J Wilkin; G Qin-sheng; A M Galich; K Vandormael; A J Yates; B Stych
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

4.  Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

Authors:  J Reginster; H W Minne; O H Sorensen; M Hooper; C Roux; M L Brandi; B Lund; D Ethgen; S Pack; I Roumagnac; R Eastell
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

5.  Identification of fractures from computerized Medicare files.

Authors:  W A Ray; M R Griffin; R L Fought; M L Adams
Journal:  J Clin Epidemiol       Date:  1992-07       Impact factor: 6.437

6.  Utility of automated data in identifying femoral shaft and subtrochanteric (diaphyseal) fractures.

Authors:  L Spangler; S M Ott; D Scholes
Journal:  Osteoporos Int       Date:  2010-12-10       Impact factor: 4.507

7.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Authors:  M R McClung; P Geusens; P D Miller; H Zippel; W G Bensen; C Roux; S Adami; I Fogelman; T Diamond; R Eastell; P J Meunier; J Y Reginster
Journal:  N Engl J Med       Date:  2001-02-01       Impact factor: 91.245

8.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

9.  Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Authors:  Charles H Chesnut; Arne Skag; Claus Christiansen; Robert Recker; Jacob A Stakkestad; Arne Hoiseth; Dieter Felsenberg; Hermann Huss; Jennifer Gilbride; Ralph C Schimmer; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2004-03-29       Impact factor: 6.741

10.  Ten years' experience with alendronate for osteoporosis in postmenopausal women.

Authors:  Henry G Bone; David Hosking; Jean-Pierre Devogelaer; Joseph R Tucci; Ronald D Emkey; Richard P Tonino; Jose Adolfo Rodriguez-Portales; Robert W Downs; Jayanti Gupta; Arthur C Santora; Uri A Liberman
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

View more
  17 in total

1.  Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.

Authors:  Z Wang; M M Ward; L Chan; T Bhattacharyya
Journal:  Osteoporos Int       Date:  2014-05-21       Impact factor: 4.507

2.  Risk profiles for acute health events after incident atrial fibrillation in patients with end-stage renal disease on hemodialysis.

Authors:  Medha Airy; Tara I Chang; Victoria Y Ding; Benjamin A Goldstein; Nisha Bansal; Jingbo Niu; Sankar D Navaneethan; Mintu P Turakhia; Wolfgang C Winkelmayer
Journal:  Nephrol Dial Transplant       Date:  2018-09-01       Impact factor: 5.992

Review 3.  Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications.

Authors:  Yoshitomo Saita; Muneaki Ishijima; Kazuo Kaneko
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

4.  Use of administrative data for national surveillance of osteoporosis and related fractures in Canada: results from a feasibility study.

Authors:  S O'Donnell
Journal:  Arch Osteoporos       Date:  2013-06-06       Impact factor: 2.617

5.  The effect of low-trauma fracture on one-year mortality rate among privately insured adults with and without neurodevelopmental disabilities.

Authors:  Daniel G Whitney; Daniel Whibley; Karl J Jepsen
Journal:  Bone       Date:  2019-09-05       Impact factor: 4.398

6.  Low-Trauma Fracture Increases 12-Month Incidence of Cardiovascular Disease for Adults With Cerebral Palsy.

Authors:  Daniel G Whitney; Rachael T Whitney; Rhonda D Prisby; Karl J Jepsen
Journal:  J Orthop Res       Date:  2019-11-11       Impact factor: 3.494

7.  Elevated fracture risk for adults with neurodevelopmental disabilities.

Authors:  Daniel G Whitney; Michelle S Caird; Karl J Jepsen; Neil S Kamdar; Christina N Marsack-Topolewski; Edward A Hurvitz; Mark D Peterson
Journal:  Bone       Date:  2019-10-24       Impact factor: 4.398

8.  Osteoporosis-related fracture case definitions for population-based administrative data.

Authors:  Lisa M Lix; Mahmoud Azimaee; Beliz Acan Osman; Patricia Caetano; Suzanne Morin; Colleen Metge; David Goltzman; Nancy Kreiger; Jerilynn Prior; William D Leslie
Journal:  BMC Public Health       Date:  2012-05-18       Impact factor: 3.295

9.  Obstructive sleep apnea and fractures in children and adolescents.

Authors:  Lisa B Matlen; Daniel G Whitney; Daniel Whibley; Erica C Jansen; Ronald D Chervin; Galit Levi Dunietz
Journal:  J Clin Sleep Med       Date:  2021-09-01       Impact factor: 4.324

10.  Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis.

Authors:  Fei Xue; Haijun Ma; Catherine Stehman-Breen; Christine Haller; Leonid Katz; Rachel B Wagman; Cathy W Critchlow
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-07-15       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.